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Abstract
Background: Recommendations to prevent the spread of vancomycin resistance have been in place since 1995 and include
guidelines for inpatient pediatric use of vancomycin. The emergence of large databases allows us to describe variation in
pediatric vancomycin across hospitals. We analyzed a database with hospitalizations for children under 18 at 421 hospitals
in 2008.
Methodology/Principal Findings: The Premier hospital 2008 database, consisting of records for 877,201 pediatric
hospitalizations in 421 hospitals, was analyzed. Stratified analyses and logistic mixed effects models were used to calculate
the probability of vancomycin use while considering random effects of hospital variation, hospital fixed effects and patient
effects, and the hierarchical structure of the data. Most hospitals (221) had fewer than 10 hospitalizations with vancomycin
use in the study period, and 47 hospitals reported no vancomycin use in 17,271 pediatric hospitalizations. At the other end
of the continuum, 21 hospitals (5.6% of hospitals) each had over 200 hospitalizations with vancomycin use, and together,
accounted for more than 50% of the pediatric hospitalizations with vancomycin use. The mixed effects modeling showed
hospital variation in the probability of vancomycin use that was statistically significant after controlling for teaching status,
urban or rural location, size, region of the country, patient ethnic group, payor status, and APR-mortality and severity codes.
Conclusions/Significance: The number and percentage of pediatric hospitalizations with vancomycin use varied greatly
across hospitals and was not explained by hospital or patient characteristics in our logistic models. Public health efforts to
reduce vancomycin use should be intensified at hospitals with highest use.
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Introduction
Vancomycin is indicated for the treatment of serious or severe
infections caused by susceptible strains of methicillin-resistant
(beta-lactam-resistant) staphylococci. It is indicated for patients
who cannot receive or who have failed to respond to other drugs,
including the penicillins or cephalosporins, and for infections
caused by vancomycin-susceptible organisms that are resistant to
other antimicrobial drugs. Because of concerns about the
development of drug-resistant bacteria, vancomycin should be
used only to treat or prevent infections that are proven or strongly
suspected to be caused by susceptible bacteria. Recommendations
to prevent the spread of vancomycin resistance have been in place
since 1995 and include guidelines for inpatient pediatric use of
vancomycin [1,2,3,4,5,6,7].
In 1999 Shah and colleagues described vancomycin use in one
hospital’s pediatric neurosurgery unit and noted vancomycin was
used primarily for prophylaxis and was inconsistent with the
Hospital Infection Control Practices Advisory Committee recom-
mendations [8]. Hopkins and colleagues evaluated use in one
hospital’s pediatric hematology-oncology unit, and concluded that
100% of the use was not consistent with CDC recommendations
[9]. Keyserling and colleagues (2003) studied 22 hospitals
belonging to the Pediatric Prevention Network (PPN) [10]. They
described series of 25 patients receiving vancomycin at each
hospital, and surveyed the physicians who prescribed the
vancomycin. They did not categorize adherence to guidelines,
but noted general patterns of use such as the low percentage (7%)
with laboratory-confirmed b-lactam-resistant organisms isolated at
the time vancomycin was prescribed, or the association of
vancomycin use with presence of indwelling vascular catheters.
Bolon and colleagues evaluated vancomycin use in children older
than 1 year at a pediatric tertiary care medical center in 2000 and
2001 [11]. They developed algorithms to evaluate whether use was
appropriate, and concluded that 35% of the initial courses were
inappropriate. Patel and colleagues studied the medical records of
200 neonates born after Septermber 2005 at 4 tertiary care
(NICUs) and concluded that 32% of the days of vancomycin use
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were inappropriate and non-adherent to the Centers for Disease
Control and Prevention 12 Step Campaign to Prevent Antimi-
crobial Resistance [3,12]. They noted non-adherence to steps 4
(Target the pathogen) and 8 (Treat infection, not contamination or
colonization). Other studies have described use, but have not
assessed guideline adherence [13,14]. The emergence of large
multi-hospital databases in the past decade offers new opportu-
nities to study patterns of vancomycin use across hospitals. In this
study, we analyzed a large database and describe variation in
pediatric vancomycin use in all children under 18 hospitalized at
421 hospitals in 2008.
Methods
We analyzed vancomycin use occurring in pediatric hospital-
izations in 2008 using the Premier hospital database, a large US
hospital-based, service-level, all-payer database, containing infor-
mation from primarily non-profit, non-governmental, community
and teaching hospitals and health systems [15]. Detailed service
level information was available for each hospital day and included
medication information and central supplies. Patient information
collected included, but was not limited to, patient demographics
(age, gender, race/ethnicity), principal and secondary diagnoses,
principal and secondary procedures, payor, length of stay, cost of
care, drug utilization, department cost and charge detail, day-of-
stay data, and physician specialty. In addition to the service-level
data recorded in most standard hospital discharge files, the
database provided a daily log of all billed items, including
procedures, medications, laboratory tests and diagnostic and
therapeutic services, at the individual patient level. Hospitals were
self-selected, choosing to provide their own data to Premier as part
of agreements by which they received access to analytic tools
developed and offered by Premier. In the study year, 2008 423
hospitals participated (99.1% with pediatric hospitalizations). Data
were entered into a hospital’s core information system, fed into
their decision support system (DSS), then sent to Premier on a
monthly or quarterly basis via a secure FTP site. Upon receiving
data from participating hospitals, Premier undertook an extensive
seven phase data validation and correction process that included
more than 95 quality assurance checks. Deidentified data were
extracted and used for statistical analysis. The study proposal was
approved by the University of Rhode Island Institutional Review
Board and informed consent requirements were waived, as
permitted under 45 CFR 46.116(c) or (d).
We calculated the number of unique hospitalizations with any
use of vancomycin and estimated the prevalence of vancomycin
use (number of hospitalizations with documentation of any
vancomycin use per 100 hospitalizations). We also estimated the
percentages vancomycin use in children over and under 1 year of
age, and the percentages of hospitalizations with use longer than 3
days duration. Patient characteristics were: age in years, gender,
race (White, African-American, other), and type of insurance
(private, government or none). Hospital characteristics were size
(small, medium, large), teaching or non-teaching, urban or rural,
and region of the country (Northeast, Midwest, South and West, as
defined by the US Census).
Logistic mixed effects modeling with two levels of hierarchy
(hospital and patient) were used to calculate the probability of
vancomycin use while considering the random effects of hospital
variation, as well as hospital fixed effects and patient effects. In our
models we included the 3 MTM All Patient Refined Diagnosis
Related Groups (APR DRGs) severity and mortality (as 4 level,
ordered categories), and International Classification of Diseases –
9th Revision – Clinical Modification (ICD-9-CM) Group Codes.
The 3 MTM APR DRGs expand the basic DRG structure and
address patient differences relating to severity of illness and risk of
mortality [16]. Severity of illness was defined as the extent of
physiologic decompensation or organ system loss of function. Risk
of mortality was defined as the likelihood of dying. The SAS
procedure, GLIMMIX was run using the events/trial syntax to
maintain the hierarchical structure of the data [17,18,19]. Models
were run in subsets of hospitalizations, for children under 1 year of
age, and further separated by ICD-9 Group Codes. Plots of odds
ratios were produced using SAS Graphics [20]. All statistical
analyses were conducted using SAS 9.2 [21].
Results
The dataset contained records for 877,201 hospitalizations of
children under 18 at time of admission with 50,879 (5.8%) being
repeat admissions. The study population was 50.9% male and
49.1% female, 48.5% white, 16.1% African-American, 12.2%
Hispanic, 3.6% Asian/Pacific Islander, 18.7% other and less than
1% American Indian. The average length of stay was 3.7 days
(median 2 days, interquartile range 2–3 days). Private insurance
paid for 46.2% of the hospital stays, government paid for 45.9%
and self-pay, no charge or other sources accounted for 7.9% of the
hospital stays. Most of the hospitalizations took place in urban
areas (89.2%) compared to rural areas (10.8%).
We validated the Premier sample of hospitalizations by
comparing characteristics of the sample to the HCUP KID
sample of pediatric hospitalizations for 2006 and details of the
validation are available in a previous publication (Lasky et al.,
2011). The Premier sample included a greater proportion of
infants born in the hospital, from Southern hospitals, from non-
teaching hospitals, and from large size hospitals compared to the
HCUP KID sample. The two samples were similar with regards to
proportions male, routine discharge status, APR-DRGs severity
and proportions urban. We did not compare the proportions of
different racial and ethnic groups in Premier to the KID because
of well documented limitations in racial and ethnic data within the
KID, high rates of missing data resulting from state differences in
collection and reporting of race and ethnicity. Vancomycin was
administered in 19,775 hospitalizations, or 2.3% of 877,201
pediatric hospitalizations in the database in 2008. In 98% of cases,
vancomycin was administered parenterally or ‘‘other’’ (this
includes ophthalmic solutions, intraocular/intravitreal injections,
catheter flushes, inhalation formulations, rectal formulations and
topical gels compounded by pharmacy) and in less than 2% of
cases, vancomycin was administered orally. Half (10,033 or
50.7%) of the courses of vancomycin were less than 3 days
duration. Males had higher prevalence of use than did females
(2.5%, 95% CI 2.5–2.6 compared to 2.0%, 95% CI 2.0–2.0),
African-Americans had higher use than did whites or other groups
(3.1%, 95% CI 3.0–3.2, 2.3%, 95% CI 2.3–2.4 and 1.8%, 95% CI
1.8–1.9 respectively), and children in the age groups 2–4 and 5–11
had higher prevalence compared to children under 2, or children
age 12–17 (6.8%, 95% CI 6.5–7.1, 6.6%, 95% CI 6.4–6.8, 1.5%,
95% CI 1.5–1.5, and 4.3%, 95% 4.2–4.4). The greatest number of
hospitalizations with vancomycin use occurred to children under 2
(10,282 or 52% of hospitalizations), however the highest preva-
lence of use occurred in children age 2–4, and 5–11 (Figure 1).
Children age 2–4 were 4.5 times more likely, children 5–11 were
4.4 times more likely, and children 12–17 were 2.9 times more
likely to receive vancomycin compared to children under 2. In
hospitalizations of children under one year with vancomycin use,
the four most frequent ICD-9 group diagnoses were: ‘‘Liveborn
infants according to type of birth’’ (ICD-9-CM V30–39) (51.83%),
Pediatric Vancomycin Use in 421 Hospitals
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‘‘Other conditions originating in the perinatal period’’ (ICD-9-CM
760–779) (14.29%), ‘‘Infections of skin and subcutaneous tissue’’
(ICD-9-CM 680–709) (6.07%), and ‘‘Congenital anomalies’’
(5.91%) (ICD-9-CM 740–759). In children age 1 or over, the
four most frequent diagnoses were: ‘‘Infections of skin and
subcutaneous tissue’’ (23.32%), ‘‘Pneumonia and influenza’’,
(9.41%) (ICD-9-CM 480–488), ‘‘Complications of surgical and
medical care, not elsewhere classifiable’’ (7.58%) (ICD-9-CM 996–
999), and ‘‘Other bacterial diseases’’ (4.41%) (030–041).
Vancomycin was administered to children at 374 hospitals in
the Premier hospital database; another 47 hospitals with 17,271
pediatric hospitalizations (13,233 under age 2) reported no
vancomycin use during 2008. The number of hospitalizations
with vancomycin use ranged from 0 to 1225 at individual
hospitals, and percentage of hospitalizations with vancomycin use
ranged from 0.0% to 33.3%. Twenty one hospitals (5.6%) had
more than 200 hospitalizations with vancomycin use, accounting
for 9,979 (50%) of the pediatric hospitalizations with vancomycin
use. Because of the skewness in distribution of vancomycin use, we
stratified hospitals by number of hospitalizations with vancomycin
use. Low volume was defined as 0 to 10, medium volume as 11–
100, and high volume as over 100. Most hospitals were
Figure 1. Vancomycin use by age group.
doi:10.1371/journal.pone.0043258.g001
Table 1. The estimates and 95% Confidence Bounds of the variance of the random hospital intercepts on the logit scale in four
models for individual diagnostic groups in children under 1.
ICD-group included in model Estimate of Random Intercept 95% Confidence Bounds
Liveborn infants according to type of birth
ICD-9-CM V30–39
1.5 1.2–1.9
Infections of skin and subcutaneous tissue
ICD-9-CM 680–709
1.5 1.1–2.2
Other conditions originating in perinatal period
ICD-9-CM 760–779
0.4 0.3–0.7
Congenital anomalies
ICD-9-CM 740–759
0.3 0.2–0.9
doi:10.1371/journal.pone.0043258.t001
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categorized as low volume (221 hospitals), 155 hospitals were
categorized as medium volume, and 45 hospitals categorized as
high volume. Within high volume hospitals, percentage of
hospitalizations with vancomycin use ranged from 1.3–12.9 (mean
percentage was 4.6, 95% CI= 3.9–5.4). Within medium volume
hospitals, percentage of hospitalizations with vancomycin use
ranged from 0.3 to 9.5 (mean percentage was 1.7, 95% CI= 1.5–
1.9). The hospitals with high volume of vancomycin use were
predominantly large (73.3%), teaching (68.9%), and urban
(97.8%) compared to the hospitals with low volume of vancomycin
use, which were 45.7% large, 19.91% teaching, and 74.21%
urban, and 95% Confidence Intervals of estimates generally did
not overlap. In 2008, 47 hospitals, or 11.16% of the hospitals in
the database, reported no vancomycin use in the entire year.
The logistic mixed effects modeling showed hospital variation in
vancomycin use. The estimated variance of the random effects
hospital intercepts for models run for children under 1, and for the
four most frequent ICD-9 Code Groups are summarized in
Table 1. The intercept estimates and the 95% Confidence Bounds
for each model do not include zero, indicating hospital variation
that is statistically significant after controlling for the other
variables in the model. The lower limits of the 95 percent
confidence intervals are above zero, indicating statistically
significant variability in the use of vancomycin depending on the
hospital in which a patient was treated.
The Odds Ratios for hospital and patient fixed effects for two of
the models are plotted in Figures 2 and 3. Variables associated
with vancomycin use were different in each of the age and ICD
groups. For example, in children under 1 year with ICD-9 group
‘‘Liveborn infants according to type of birth’’ increased APR-
DRG severity of illness was associated with over 6 times the use of
vancomycin, but in children under 1 year with ICD-9 group
‘‘Infections of skin and subcutaneous tissue’’ use of vancomycin
was almost 2 times as frequent in children with increased APR-
DRG severity (although the 95%CI slightly overlapped 1). Both
models showed an association between increased APR-DRG
severity of illness and vancomycin use, but the magnitude of the
effect differed greatly in the two patient groups. Another example
is the effect of rural vs. urban status of the hospital. Rural or urban
status of the hospital was statistically significant in predicting
vancomycin use in children under 1 year with ICD-9 group
‘‘Liveborn infants according to type of birth’’ and with ICD-9
group ‘‘Infections of skin and subcutaneous tissue’’, but the
direction of the effect was different in each group of patients. For
children under 1 year with ICD-9 group ‘‘Liveborn infants
according to type of birth’’ rural hospitals had lower vancomycin
use than did urban hospitals, but for children under 1 year with
ICD-9 group ‘‘Infections of skin and subcutaneous tissue’’ rural
hospitals had higher vancomycin use than did urban hospitals.
Another example can be seen with patient’s insurance coverage. In
Figure 2. Odds Ratios for models in patients under 1 year of age ICD-9-CM group ‘‘Liveborn infants according to type of birth’’.
doi:10.1371/journal.pone.0043258.g002
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children under 1 year with ICD-9 group ‘‘Liveborn infants
according to type of birth’’ those with government insurance had
slightly higher vancomycin use than did those with private
insurance, and those with no insurance had less vancomycin use
than those with private insurance. In children under 1 year with
ICD-9 group ‘‘Infections of skin and subcutaneous tissue’’
insurance coverage was not associated with vancomycin use.
Discussion
Most hospitals (221) had fewer than 10 hospitalizations with
vancomycin use in the study period, and 47 hospitals reported no
vancomycin use in 17,271 pediatric hospitalizations. At the other
end of the continuum, 21 hospitals (5.6% of hospitals) each had
over 200 hospitalizations with vancomycin use, and together,
accounted for more than 50% of the pediatric hospitalizations with
vancomycin use. Percentage of hospitalizations with vancomycin
use ranged up to 33.3% when hospitals with few pediatric
hospitalizations were kept in the sample, and for this reason,
percentage, by itself, may not be a useful indicator in small
hospitals. In hospitals with more than 100 hospitalizations with
vancomycin use, the percentage with vancomycin use ranged from
1.26 to 12.90, a 10 fold range in the probability of vancomycin
use. Without knowing how percentage correlates with inappro-
priate use, one might begin by evaluating vancomycin use in
hospitals with greater than 100 hospitalizations with vancomycin
use and greater than 4 or 5% of hospitalizations having
vancomycin. The two measures, absolute number of hospitaliza-
tions and percentage of hospitalizations with vancomycin use, can
be used to identify and target hospitals for evaluation and potential
interventions.
The limitations of the study include those inherent in secondary
analysis of large databases. In this database, the ICD-9 code
referred to the entire hospitalization rather than the indication for
medication use, and we were unable to analyze the relationship
between Methicillen-resistant Staphylococcus aureus (MRSA)
occurrence and vancomycin use. The Premier database codes
for MRSA changed during 2008 and future analyses will be able to
describe MRSA variation. Although we could not analyze the data
from our study year, 2008, a preliminary analysis of 2011 data
showed MRSA codes in only 9.6% of hospitalizations with
vancomycin use. Future analyses whether this is explained by
undercoding MRSA, inappropriate use of vancomycin, or some
other difference.
The definition of vancomycin use as any use during the hospital
stay is both a weakness and a strength. It does not permit analysis
of dose or duration which will be of interest in future studies, but it
does permit estimates of percentages of hospitalized children
exposed to vancomycin use. This is of interest when planning
clinical studies, comparative effectiveness research, policy and
labeling priorities, and other issues. The percentage (or prevalence)
Figure 3. Odds Ratios for models in patients under 1 year of age ICD-9-CM group ‘‘Infections of skin and subcutaneous tissue’’.
doi:10.1371/journal.pone.0043258.g003
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may provide a different perspective than that developed as a result
of using numerator data only. For example, Keyserling and
colleagues (2003) tabulated vancomycin courses and identified the
largest number as occurring in neonatology services, and then
suggested that neonatal intensive care units (NICUs) improve their
vancomycin use [10]. We also found the highest number of uses in
children under 2 years of age, but the lowest probability of use in
children under 2 years of age (1.5%) compared to other age groups
(4.3–6.8%). This may reflect the large number of healthy
newborns in databases and programs to measure use of
vancomycin in neonates will need to define a denominator, in
addition to measuring the numerator, as is currently done.
The stratified analysis and the logistic modeling consistently
document variation in vancomycin use by individual hospital, after
considering independent effects of hospital and patient character-
istics. The mixed models allowed us to estimate variation in the use
of vancomycin by hospital in children with the same ICD-9 group
codes. The intercepts measure the differences between hospitals,
controlling for other effects in the model such as hospital and
patient characteristics [18]. For every ICD-9 Group modeled,
hospital-to-hospital variation and 95% Confidence Bounds of the
intercept excluded zero, after controlling for hospital and patient
effects.
Until recently, few studies have compared antibiotic use across
large numbers of hospitals or geography, however the establish-
ment of the National Healthcare Safety Network by the Centers
for Disease Control and Prevention will allow regular comparisons
across hospitals [22]. Geographic variation in use of antibiotics has
also recently been documented in the United States [23].
The analyses presented here are also a step forward in studying
pediatric hospital variation; previous researchers have used
hierarchical models to consider hospital variation in adults, for
example by studying maternity length of stay or mortality in
patients undergoing coronary artery bypass surgery (CABG)
[18,24]. Hospital variation in care of adults has been studied for
several decades, much of it made possible by large Medicare
claims databases [25]. Only recently have aggregated data for
pediatric hospitalizations been available. Bowman and colleagues
(2005) recently demonstrated variation in management of
pediatric splenic injuries and Weiss et al (2009) have demonstrated
variation in use of corticosteroids, opioids and nonsteroidal anti-
inflammatory drug, diagnostic imaging, and renal biopsy in
children with Henoch Scho¨nlein purpura [26,27]. The public
health implications of these data are that efforts to control
vancomycin use may be channeledo hospitals with high numbers
and prevalence of vancomycin use. While it seems intuitive that
high prevalence will lead to high volume, and vice versa, some
high volume hospitals maintain a prevalence below 3 per cent,
while others range above 7 percent, almost to 13 percent.
Presently, the message to reduce vancomycin use is broadcast to
the entire healthcare community [2,28]. General principles of
judicious antibiotic use are applicable to all hospitals and providers
for all antibiotics, and these data may be used to channel intensive
stewardship activities and intervention research data to hospitals
with the highest volume and prevalence of vancomycin use.
While the Premier hospital database contains information about
presence or absence of laboratory testing, it does not include
information about test results. Future research relating vancomy-
cin use to laboratory test results may need to budget for and obtain
access to hospital charts or to laboratory-based infection surveil-
lance data. We restricted the current analysis to one year, 2008;
access to other years of data would permit assessment of trends
over the last several years. Finally, further study may prepare the
way for comparative effectiveness research, by identifying and
comparing children with similar conditions treated with and
without vancomycin, and relating the treatment patterns to
outcomes.
Our key findings include the skewness of the distribution of
vancomycin use throughout hospitals, the importance of denom-
inator data in assessing vancomycin use, and hospital variation in
vancomycin use, not explained by hospital or patient character-
istics including: bed size, teaching status, region of the country,
rural or urban geography, and patient sex, race, APR-DRG risk of
mortality and APR-DRG severity of illness.
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